Abstract
Aims/hypothesis: Established autoimmune markers of type 1 diabetes, including islet cell autoantibodies (ICA) and autoantibodies to glutamic acid decarboxylase (GADA) have been used to screen people presenting with type 2 diabetes for latent autoimmune diabetes in adults. We have examined the prevalence of autoantibodies to protein tyrosine phosphatase isoforms IA-2 (IA-2A) and IA-2β/phogrin (IA-2βA) in a cohort of adult UKPDS patients thought to have type 2 diabetes, and investigated the possible role of these autoantibodies in predicting requirement for insulin therapy. Methods: IA-2A and IA-2βA were measured by a validated radioimmunoassay with human recombinant autoantigens in 4,169 white Caucasian patients aged 25-65 years and newly diagnosed with type 2 diabetes. The clinical requirement for insulin therapy within 6 years was examined in 2,556 patients not randomised to insulin. Results: IA-2A and IA-2βA were present in 2.2 and 1.4%, respectively, of these patients. IA-2A were more prevalent in younger patients (p for trend
Original language | English |
---|---|
Pages (from-to) | 703-708 |
Number of pages | 6 |
Journal | Diabetologia |
Volume | 48 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2005 |
Keywords
- GADA
- IA2A
- ICA
- Insulin requirement
- Islet cell autoantibodies
- Type 2 diabetes
- UKPDS
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism